CONTEXT: Antagonism of protein kinase Cbeta (PKCbeta) restores endothelial function in experimental models of diabetes and prevents vascular dysfunction in response to hyperglycemia in healthy humans. OBJECTIVE: We tested the hypothesis that PKCbeta antagonism would improve vascular function in subjects with type 2 diabetes compared with healthy control subjects. DESIGN: The effect of PKCbeta was evaluated in a randomized, placebo-controlled, double-blinded crossover trial. SETTING: The study was performed in the outpatient setting of a university medical center. PARTICIPANTS: Thirteen subjects with type 2 diabetes without evidence of cardiovascular disease and 15 healthy control subjects were recruited via newspaper advertisement. INTERVENTION: Subjects underwent a randomized, double-blind, crossover, placebo-controlled trial of the selective PKCbeta antagonist ruboxistaurin mesylate. Subjects received each treatment for 14 d. MAIN OUTCOME MEASURE: Endothelium-dependent and endothelium-independent vasodilation of forearm resistance vessels was measured with mercury-in-silastic, strain-gauge plethysmography during intraarterial administration of methacholine chloride and verapamil, respectively. Markers of inflammation, fibrinolysis, endothelial damage, and oxidative stress were measured after each treatment. RESULTS:Endothelium-dependent vasodilation of forearm resistance vessels was attenuated in diabetic subjects when compared with healthy subjects (P=0.001). Endothelium-independent vasodilation did not differ between groups (P value not significant). Ruboxistaurin did not significantly change endothelium-dependent or endothelium-independent vasodilation or blood-based markers of inflammation, fibrinolysis, endothelial damage, and oxidative stress in either diabetic or healthy subjects. CONCLUSION:Endothelial dysfunction of forearm resistance vessels was not improved by 2 wk of selective PKCbeta inhibition in patients with diabetes. These results suggest that PKCbeta does not contribute significantly to vascular dysfunction in otherwise healthy patients with type 2 diabetes.
RCT Entities:
CONTEXT: Antagonism of protein kinase Cbeta (PKCbeta) restores endothelial function in experimental models of diabetes and prevents vascular dysfunction in response to hyperglycemia in healthy humans. OBJECTIVE: We tested the hypothesis that PKCbeta antagonism would improve vascular function in subjects with type 2 diabetes compared with healthy control subjects. DESIGN: The effect of PKCbeta was evaluated in a randomized, placebo-controlled, double-blinded crossover trial. SETTING: The study was performed in the outpatient setting of a university medical center. PARTICIPANTS: Thirteen subjects with type 2 diabetes without evidence of cardiovascular disease and 15 healthy control subjects were recruited via newspaper advertisement. INTERVENTION: Subjects underwent a randomized, double-blind, crossover, placebo-controlled trial of the selective PKCbeta antagonist ruboxistaurin mesylate. Subjects received each treatment for 14 d. MAIN OUTCOME MEASURE: Endothelium-dependent and endothelium-independent vasodilation of forearm resistance vessels was measured with mercury-in-silastic, strain-gauge plethysmography during intraarterial administration of methacholine chloride and verapamil, respectively. Markers of inflammation, fibrinolysis, endothelial damage, and oxidative stress were measured after each treatment. RESULTS: Endothelium-dependent vasodilation of forearm resistance vessels was attenuated in diabetic subjects when compared with healthy subjects (P=0.001). Endothelium-independent vasodilation did not differ between groups (P value not significant). Ruboxistaurin did not significantly change endothelium-dependent or endothelium-independent vasodilation or blood-based markers of inflammation, fibrinolysis, endothelial damage, and oxidative stress in either diabetic or healthy subjects. CONCLUSION: Endothelial dysfunction of forearm resistance vessels was not improved by 2 wk of selective PKCbeta inhibition in patients with diabetes. These results suggest that PKCbeta does not contribute significantly to vascular dysfunction in otherwise healthy patients with type 2 diabetes.
Authors: Keiko Naruse; Christian Rask-Madsen; Noriko Takahara; Sung-woo Ha; Kiyoshi Suzuma; Kerrie J Way; Judith R C Jacobs; Allen C Clermont; Kohjiro Ueki; Yuzuru Ohshiro; Junqing Zhang; Allison B Goldfine; George L King Journal: Diabetes Date: 2006-03 Impact factor: 9.461
Authors: Katherine R Tuttle; George L Bakris; Robert D Toto; Janet B McGill; Kuolung Hu; Pamela W Anderson Journal: Diabetes Care Date: 2005-11 Impact factor: 19.112
Authors: Lloyd Paul Aiello; Matthew D Davis; Aniz Girach; Keri A Kles; Roy C Milton; Matthew J Sheetz; Louis Vignati; Xin Eric Zhi Journal: Ophthalmology Date: 2006-09-20 Impact factor: 12.079
Authors: Aaron I Vinik; Vera Bril; Peter Kempler; William J Litchy; Solomon Tesfaye; Karen L Price; Edward J Bastyr Journal: Clin Ther Date: 2005-08 Impact factor: 3.393
Authors: Carolina M Casellini; Patricia M Barlow; Amanda L Rice; Melissa Casey; Kathryn Simmons; Gary Pittenger; Edward J Bastyr; Anne M Wolka; Aaron I Vinik Journal: Diabetes Care Date: 2007-04 Impact factor: 19.112
Authors: Anna Bryland; Anders Wieslander; Ola Carlsson; Thomas Hellmark; Gabriela Godaly Journal: Diab Vasc Dis Res Date: 2011-11-01 Impact factor: 3.291